{
  "investigation_timestamp": "2025-08-16T20:37:56.281558",
  "data_sources": {
    "system_features": [
      "Dr. Peptide AI Chat",
      "Enhanced Clinical Database",
      "Multi-step Assessment Wizard",
      "File Upload & Analysis",
      "Functional Medicine Protocols"
    ]
  },
  "api_endpoints": {
    "homepage_stats": {
      "protocols": 60,
      "practitioners": 9,
      "success_rate": 95,
      "support_availability": "24/7",
      "total_assessments": 181
    },
    "enhanced_library": {
      "count": 59,
      "sample_data": [
        {
          "id": "d3bf2969-1f1b-4369-ac5f-6f324ee073b0",
          "name": "BPC-157",
          "aliases": [
            "Body Protection Compound-157",
            "Pentadecapeptide BPC 157",
            "PL 14736"
          ],
          "sequence": "GEPPPGKPADDAGLV",
          "molecular_weight": 1419.53,
          "category": "Healing & Regenerative",
          "description": "Stable gastric pentadecapeptide with powerful healing and anti-inflammatory properties, derived from gastric protective protein BPC",
          "mechanism_of_action": "Promotes angiogenesis, accelerates healing of various tissues including tendons, ligaments, muscle, bone, and GI tract. Modulates nitric oxide pathways, growth hormone-IGF-1 axis, and VEGF expression.",
          "clinical_indications": [
            "Tendon and ligament injuries",
            "Muscle tears and strains",
            "Gastric ulcers and inflammatory bowel conditions",
            "Joint pain and arthritis",
            "Wound healing and tissue repair",
            "Post-surgical recovery",
            "Neuroprotection and brain injury recovery"
          ],
          "complete_dosing_schedule": {
            "standard_protocol": "200-300 mcg twice daily for 2-4 weeks",
            "acute_injury": "400-500 mcg twice daily for 7-14 days, then 200-300 mcg daily",
            "chronic_conditions": "200 mcg daily for 4-8 weeks with 2-week breaks",
            "gastric_issues": "250 mcg twice daily for 2-4 weeks",
            "maintenance": "100-200 mcg 3 times per week"
          },
          "administration_techniques": {
            "injection_sites": [
              "Abdomen",
              "Thigh",
              "Upper arm",
              "Near injury site (local injection)"
            ],
            "injection_depth": "Subcutaneous (45-degree angle)",
            "preparation": "Reconstitute with bacteriostatic water, store refrigerated up to 30 days",
            "timing": "Morning and evening, can be taken with or without food",
            "rotation": "Rotate injection sites every 3-4 injections to prevent irritation"
          },
          "safety_profile": {
            "common_side_effects": [
              {
                "effect": "Mild injection site irritation",
                "frequency": "10-15%"
              },
              {
                "effect": "Temporary fatigue",
                "frequency": "5-8%"
              },
              {
                "effect": "Headache",
                "frequency": "3-5%"
              }
            ],
            "rare_side_effects": [
              "Allergic reaction",
              "Excessive tissue growth (with very high doses)"
            ],
            "drug_interactions": "Generally safe with most medications, monitor with anticoagulants"
          },
          "contraindications_and_precautions": {
            "absolute_contraindications": [
              "Active malignancy",
              "Known hypersensitivity to BPC-157"
            ],
            "relative_contraindications": [
              "Pregnancy and breastfeeding",
              "Severe cardiovascular disease"
            ],
            "precautions": [
              "Start with lower doses in sensitive patients",
              "Monitor injection sites for excessive reaction",
              "Discontinue if unusual tissue growth occurs"
            ]
          },
          "expected_timelines": {
            "initial_effects": "3-7 days for acute injuries",
            "significant_improvement": "2-3 weeks for most conditions",
            "maximum_benefits": "4-6 weeks for chronic issues",
            "long_term_results": "Benefits may persist 2-4 weeks after discontinuation"
          },
          "monitoring_requirements": {
            "baseline_assessment": [
              "Complete blood count",
              "Comprehensive metabolic panel",
              "Inflammation markers (CRP, ESR)"
            ],
            "ongoing_monitoring": [
              "Weekly assessment of target symptoms",
              "Injection site examination",
              "Overall wellness evaluation"
            ],
            "safety_monitoring": [
              "Monthly CBC during extended use",
              "Liver function if using >8 weeks"
            ]
          },
          "scientific_references": [
            {
              "title": "BPC 157, a pentadecapeptide with documented healing properties",
              "authors": "Sikiric P, Rucman R, Turkovic B, et al.",
              "journal": "European Journal of Pharmacology",
              "year": 2018,
              "pubmed_id": "29432751",
              "key_finding": "Demonstrates potent healing effects across multiple tissue types"
            },
            {
              "title": "Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract",
              "authors": "Sikiric P, Seiwerth S, Rucman R, et al.",
              "journal": "Current Pharmaceutical Design",
              "year": 2011,
              "pubmed_id": "21443487",
              "key_finding": "Effective in treating various GI disorders"
            }
          ],
          "functional_medicine_approach": {
            "root_cause_focus": "Addresses underlying inflammatory pathways and tissue dysfunction",
            "integrative_protocols": "Combines well with anti-inflammatory diet, targeted nutrients (omega-3s, curcumin), and lifestyle modifications",
            "biomarker_optimization": "Improves inflammatory markers, tissue repair indicators, and functional movement assessments",
            "patient_empowerment": "Educate on proper injection technique, symptom tracking, and lifestyle factors that support healing"
          },
          "cost_considerations": {
            "typical_cost": "$80-120 per month",
            "insurance_coverage": "Not typically covered",
            "cost_effectiveness": "High for injury recovery, moderate for preventive use"
          },
          "created_at": "2025-08-07T16:28:01.174000"
        },
        {
          "id": "6c5f7d4a-b3b6-4be9-b61f-18c9b3fa766f",
          "name": "TB-500",
          "aliases": [
            "Thymosin Beta-4",
            "T\u03b24",
            "TMSB4X"
          ],
          "sequence": "SDKPDMAEIEKFDKSKLKKTETQEKNPLPSKETIEQEKQAGES",
          "molecular_weight": 4963.4,
          "category": "Healing & Regenerative",
          "description": "Naturally occurring peptide present in most cells, plays crucial role in wound healing, cell migration, and angiogenesis",
          "mechanism_of_action": "Promotes cell migration, angiogenesis, and wound healing through actin regulation. Inhibits inflammatory cytokines and promotes tissue repair.",
          "clinical_indications": [
            "Muscle injuries and strains",
            "Tendon and ligament damage",
            "Wound healing acceleration",
            "Hair loss (alopecia)",
            "Cardiovascular protection",
            "Post-surgical recovery",
            "Chronic fatigue syndrome"
          ],
          "complete_dosing_schedule": {
            "loading_phase": "5-10 mg twice weekly for 4-6 weeks",
            "maintenance_phase": "2-5 mg once weekly",
            "acute_injury": "10 mg twice weekly for 2-4 weeks",
            "hair_restoration": "2-5 mg weekly for 12-16 weeks",
            "athletic_recovery": "5 mg twice weekly during intense training"
          },
          "administration_techniques": {
            "injection_sites": [
              "Abdomen",
              "Deltoid",
              "Thigh",
              "Injured area (local injection)"
            ],
            "injection_depth": "Subcutaneous or intramuscular",
            "preparation": "Reconstitute with bacteriostatic water, stable for 30 days refrigerated",
            "timing": "Can be administered any time of day",
            "special_considerations": "Larger volume injection due to higher dose"
          },
          "safety_profile": {
            "common_side_effects": [
              {
                "effect": "Injection site soreness",
                "frequency": "15-20%"
              },
              {
                "effect": "Temporary fatigue",
                "frequency": "8-12%"
              },
              {
                "effect": "Mild flu-like symptoms",
                "frequency": "5-8%"
              }
            ],
            "rare_side_effects": [
              "Allergic reaction",
              "Excessive scar tissue formation"
            ],
            "drug_interactions": "No known significant interactions"
          },
          "contraindications_and_precautions": {
            "absolute_contraindications": [
              "Active malignancy",
              "Hypersensitivity to TB-500"
            ],
            "relative_contraindications": [
              "Pregnancy and lactation",
              "Severe immune dysfunction"
            ],
            "precautions": [
              "Monitor for excessive tissue growth",
              "Use sterile injection techniques",
              "Store properly to maintain potency"
            ]
          },
          "expected_timelines": {
            "initial_effects": "1-2 weeks for acute injuries",
            "significant_improvement": "3-4 weeks for most conditions",
            "maximum_benefits": "6-8 weeks for chronic issues",
            "long_term_results": "Effects may continue 4-6 weeks post-treatment"
          },
          "monitoring_requirements": {
            "baseline_assessment": [
              "Complete physical exam",
              "Injury assessment",
              "Blood work"
            ],
            "ongoing_monitoring": [
              "Weekly progress evaluation",
              "Range of motion testing",
              "Pain scale assessment"
            ],
            "safety_monitoring": [
              "Monthly check-ins during extended use",
              "Watch for unusual tissue growth"
            ]
          },
          "scientific_references": [
            {
              "title": "Thymosin \u03b24: a novel regulator of inflammation, angiogenesis, and tissue repair",
              "authors": "Goldstein AL, Hannappel E, Kleinman HK",
              "journal": "Annals of the New York Academy of Sciences",
              "year": 2005,
              "pubmed_id": "16110537",
              "key_finding": "Demonstrates powerful tissue repair and anti-inflammatory properties"
            }
          ],
          "functional_medicine_approach": {
            "root_cause_focus": "Addresses cellular repair mechanisms and inflammatory dysfunction",
            "integrative_protocols": "Synergistic with collagen support, vitamin C, zinc, and regenerative therapies",
            "biomarker_optimization": "Improves tissue repair markers, reduces inflammatory cytokines",
            "patient_empowerment": "Education on injury prevention, proper movement patterns, recovery optimization"
          },
          "cost_considerations": {},
          "created_at": "2025-08-07T16:28:01.175000"
        },
        {
          "id": "ab61a7b1-6a42-4df9-b6f6-b7607d95bc35",
          "name": "GHK-Cu",
          "aliases": [
            "Copper Peptide",
            "GHK-Copper",
            "Copper Tripeptide-1"
          ],
          "sequence": "Gly-His-Lys-Cu",
          "molecular_weight": 340.0,
          "category": "Anti-Aging & Regenerative",
          "description": "Naturally occurring copper-binding peptide with potent anti-aging, healing, and tissue remodeling properties",
          "mechanism_of_action": "Stimulates collagen and elastin synthesis, promotes wound healing, acts as antioxidant and anti-inflammatory agent. Chelates copper for enhanced bioavailability.",
          "clinical_indications": [
            "Skin aging and wrinkles",
            "Hair loss and thinning",
            "Wound healing",
            "Acne scarring",
            "Sun damage repair",
            "Post-procedure recovery",
            "Tissue regeneration"
          ],
          "complete_dosing_schedule": {
            "topical_application": "Apply 1-2% cream twice daily to affected areas",
            "injection_protocol": "1-3 mg subcutaneously 2-3 times weekly",
            "cosmetic_enhancement": "2 mg twice weekly for 8-12 weeks",
            "hair_restoration": "2-3 mg weekly for 12-16 weeks",
            "anti_aging": "1-2 mg twice weekly ongoing"
          },
          "administration_techniques": {
            "topical_method": "Clean skin, apply thin layer, allow absorption",
            "injection_sites": [
              "Face/neck area",
              "Scalp (for hair)",
              "Target skin areas"
            ],
            "injection_depth": "Shallow subcutaneous or intradermal",
            "preparation": "Pre-mixed solutions available, or reconstitute powder forms",
            "timing": "Evening application preferred for topical use"
          },
          "safety_profile": {
            "common_side_effects": [
              {
                "effect": "Mild skin irritation",
                "frequency": "10-15%"
              },
              {
                "effect": "Temporary blue-green discoloration",
                "frequency": "5-8%"
              },
              {
                "effect": "Initial skin sensitivity",
                "frequency": "8-12%"
              }
            ],
            "rare_side_effects": [
              "Allergic contact dermatitis",
              "Excessive copper accumulation (with very high doses)"
            ],
            "drug_interactions": "Avoid with other copper-containing supplements"
          },
          "contraindications_and_precautions": {
            "absolute_contraindications": [
              "Wilson's disease",
              "Copper sensitivity/allergy"
            ],
            "relative_contraindications": [
              "Active skin infections",
              "Pregnancy (topical use generally safe)"
            ],
            "precautions": [
              "Start with lower concentrations",
              "Perform patch test before full application",
              "Monitor copper levels with extended use"
            ]
          },
          "expected_timelines": {
            "initial_effects": "2-4 weeks for skin improvements",
            "significant_improvement": "6-8 weeks for anti-aging effects",
            "maximum_benefits": "12-16 weeks for full regenerative effects",
            "maintenance_required": "Ongoing use needed to maintain benefits"
          },
          "monitoring_requirements": {
            "baseline_assessment": [
              "Skin condition evaluation",
              "Hair density measurement",
              "Copper levels"
            ],
            "ongoing_monitoring": [
              "Monthly skin assessments",
              "Photo documentation",
              "Side effect monitoring"
            ],
            "safety_monitoring": [
              "Copper levels every 3 months with injections",
              "Liver function if long-term use"
            ]
          },
          "scientific_references": [
            {
              "title": "The copper-binding peptide GHK-Cu in skin aging and wound healing",
              "authors": "Pickart L, Vasquez-Soltero JM, Margolina A",
              "journal": "Journal of Aging Research & Clinical Practice",
              "year": 2015,
              "key_finding": "Demonstrates significant anti-aging and wound healing properties"
            }
          ],
          "functional_medicine_approach": {
            "root_cause_focus": "Addresses cellular aging processes and oxidative damage",
            "integrative_protocols": "Combines with antioxidant therapy, collagen support, and healthy aging protocols",
            "biomarker_optimization": "Improves skin elasticity, collagen density, and cellular repair markers"
          },
          "cost_considerations": {},
          "created_at": "2025-08-07T16:28:01.176000"
        }
      ]
    },
    "peptides_database": {
      "count": 60,
      "sample_data": [
        {
          "name": "Semaglutide",
          "category": "Weight Management",
          "indications": [
            "Type 2 Diabetes Mellitus",
            "Obesity Management"
          ],
          "mechanism_of_action": "GLP-1 receptor agonist that enhances glucose-dependent insulin secretion, suppresses glucagon release, delays gastric emptying, and promotes satiety through central nervous system pathways.",
          "evidence_level": "Level 1A evidence with multiple RCTs showing 15-20% weight reduction and HbA1c reduction of 1.5-2.0%",
          "regulatory_status": "FDA approved for T2DM and chronic weight management",
          "complete_dosing_schedule": {
            "standard_protocol": "0.25mg weekly \u00d7 4 weeks \u2192 0.5mg weekly \u00d7 4 weeks \u2192 1.0mg weekly (maintenance)",
            "dosing_range": "0.25mg - 2.4mg weekly",
            "frequency": "Once weekly",
            "route": "Subcutaneous injection",
            "reconstitution": "Pre-filled pen, no reconstitution required"
          },
          "administration_techniques": {
            "technique": "Subcutaneous injection using 90-degree angle with provided pen device",
            "sites": [
              "Abdomen (preferred)",
              "Thigh",
              "Upper arm"
            ],
            "storage": "Refrigerate 36-46\u00b0F (2-8\u00b0C). Room temperature max 28 days.",
            "preparation": "Remove from refrigerator 15-30 minutes before injection. Check for particles/discoloration.",
            "timing": "Same day each week, any time of day, with or without food"
          },
          "safety_profile": {
            "contraindications": [
              "Personal/family history of medullary thyroid carcinoma",
              "Multiple Endocrine Neoplasia syndrome type 2",
              "Severe gastrointestinal disease",
              "Type 1 diabetes (relative contraindication)"
            ],
            "side_effects": [
              "Nausea (most common, typically transient)",
              "Vomiting, diarrhea, constipation",
              "Abdominal pain, headache",
              "Fatigue, dizziness",
              "Injection site reactions"
            ],
            "monitoring_required": [
              "Body weight and BMI monthly",
              "Blood glucose and HbA1c quarterly",
              "Lipid panel every 6 months",
              "Kidney function (eGFR, creatinine)",
              "Amylase/lipase if abdominal symptoms"
            ]
          },
          "expected_timelines": {
            "onset": "Weight loss begins within 2-4 weeks",
            "peak_effects": "Maximum weight loss at 60-68 weeks",
            "duration": "Effects maintain with continued use",
            "full_therapeutic_effect": "12-16 weeks for full therapeutic effect"
          },
          "scientific_references": [
            "Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. NEJM. 2021;384(11):989-1002.",
            "Davies M, et al. Semaglutide 2\u00b74 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021;397(10278):971-984.",
            "Rubino D, et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance. JAMA. 2021;325(14):1414-1425."
          ]
        },
        {
          "name": "Tirzepatide",
          "category": "Weight Management",
          "indications": [
            "Type 2 Diabetes Mellitus",
            "Obesity Management"
          ],
          "mechanism_of_action": "Dual GIP/GLP-1 receptor agonist providing superior glycemic control and weight loss through enhanced insulin sensitivity, delayed gastric emptying, and central appetite suppression.",
          "evidence_level": "Level 1A evidence with RCTs showing up to 22.5% weight reduction and superior efficacy to semaglutide",
          "regulatory_status": "FDA approved for T2DM and chronic weight management",
          "complete_dosing_schedule": {
            "standard_protocol": "2.5mg weekly \u00d7 4 weeks \u2192 5mg weekly \u00d7 4 weeks \u2192 7.5mg weekly \u2192 10mg-15mg weekly (maintenance)",
            "dosing_range": "2.5mg - 15mg weekly",
            "frequency": "Once weekly",
            "route": "Subcutaneous injection",
            "reconstitution": "Pre-filled pen, no reconstitution required"
          },
          "administration_techniques": {
            "technique": "Subcutaneous injection with pre-filled pen device",
            "sites": [
              "Abdomen",
              "Thigh",
              "Upper arm"
            ],
            "storage": "Refrigerate 36-46\u00b0F (2-8\u00b0C)",
            "preparation": "Allow to reach room temperature before injection",
            "timing": "Same day each week, with or without food"
          },
          "safety_profile": {
            "contraindications": [
              "Personal/family history of medullary thyroid carcinoma",
              "Multiple Endocrine Neoplasia syndrome type 2",
              "Severe gastrointestinal disease"
            ],
            "side_effects": [
              "Nausea, vomiting, diarrhea",
              "Decreased appetite",
              "Constipation",
              "Abdominal pain",
              "Injection site reactions"
            ],
            "monitoring_required": [
              "Body weight monthly",
              "HbA1c quarterly",
              "Kidney function",
              "Lipase if symptoms"
            ]
          },
          "expected_timelines": {
            "onset": "Weight loss within 2-4 weeks",
            "peak_effects": "Maximum weight loss at 72 weeks",
            "duration": "Sustained with continued use",
            "full_therapeutic_effect": "16-20 weeks for maximum benefit"
          },
          "scientific_references": [
            "Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. NEJM. 2022;387(3):205-216.",
            "Frias JP, et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. NEJM. 2021;385(6):503-515."
          ]
        },
        {
          "name": "AOD-9604",
          "category": "Weight Management",
          "indications": [
            "Fat Loss",
            "Body Composition Improvement"
          ],
          "mechanism_of_action": "Modified fragment of human growth hormone (hGH) that retains the fat-reducing effects without growth-promoting effects. Stimulates lipolysis and inhibits lipogenesis.",
          "evidence_level": "Level 2B evidence showing significant fat loss, particularly in abdominal region, with minimal side effects",
          "regulatory_status": "Human GRAS status in USA, investigational use",
          "complete_dosing_schedule": {
            "standard_protocol": "300-400mcg daily in morning, fasted state",
            "dosing_range": "300-500mcg daily",
            "frequency": "Once daily",
            "route": "Subcutaneous injection",
            "reconstitution": "Reconstitute with bacteriostatic water"
          },
          "administration_techniques": {
            "technique": "Subcutaneous injection at 45-degree angle",
            "sites": [
              "Abdomen",
              "Thigh"
            ],
            "storage": "Refrigerate after reconstitution, stable 30 days",
            "preparation": "Gentle reconstitution, avoid vigorous shaking",
            "timing": "Morning administration, 30 minutes before first meal"
          },
          "safety_profile": {
            "contraindications": [
              "Pregnancy, breastfeeding",
              "Active cancer"
            ],
            "side_effects": [
              "Generally well-tolerated",
              "Some users report headache, fatigue",
              "Injection site reactions"
            ],
            "monitoring_required": [
              "Body composition changes",
              "Weight loss progress",
              "General health markers"
            ]
          },
          "expected_timelines": {
            "onset": "Initial fat loss effects within 2-3 weeks",
            "peak_effects": "Maximum benefits at 12-16 weeks",
            "duration": "Typically cycled 12-16 weeks with 4-week breaks",
            "full_therapeutic_effect": "12-16 weeks for sustained results"
          },
          "scientific_references": [
            "Heffernan MA, et al. The effects of human GH and its lipolytic fragment on lipid metabolism. Endocrinology. 2001;142(9):3887-97.",
            "Ng FM, et al. Growth hormone fragment 176-191 stimulates lipolysis. Biochem Biophys Res Commun. 2000;279(1):77-81."
          ]
        }
      ]
    }
  },
  "count_analysis": {
    "homepage_protocols": 60,
    "enhanced_library": 59,
    "peptides_database": 60,
    "expected_peptides": 60,
    "expected_protocols": 87
  },
  "findings": [
    "Homepage API reports 60 protocols",
    "\u26a0\ufe0f  DISCREPANCY: Expected 87 protocols, found 60",
    "Enhanced library contains 59 PROTOCOL entries (has dosing schedules)",
    "Enhanced library contains 59 PEPTIDE entries (has sequences)",
    "Peptides database contains 60 entries with PROTOCOL information",
    "\u2705 MATCH: Found expected 60 peptides in comprehensive database",
    "\u2705 CONFIRMED: Peptides database has expected 60 peptides",
    "\u274c DISCREPANCY: Homepage shows 60 protocols, expected 87",
    "\u2705 CONFIRMED: Enhanced Library contains PROTOCOL data (dosing schedules, administration)",
    "\ud83d\udd0d FINDING: Enhanced Library contains BOTH peptide data AND protocol data",
    "\ud83d\udca1 HYPOTHESIS: Enhanced Library entries are comprehensive peptide protocols"
  ],
  "recommendations": [
    "Need to find the correct data source for 87 protocols",
    "Enhanced Library appears to be the protocol source, not just peptides",
    "INVESTIGATE: Check if ENHANCED_CLINICAL_PEPTIDES should be expanded to 87 entries",
    "INVESTIGATE: Check if there are additional protocol sources not being counted",
    "INVESTIGATE: Verify if user's expectation of 87 protocols is correct",
    "CONSIDER: Maybe protocols include combinations, variations, or different dosing protocols"
  ]
}